Form 4 Tracker
Michelle Gilson

CHIEF FINANCIAL OFFICER; Director · 7 filings · Latest: Aug 3, 2026

Arcellx, Inc.
Rani Therapeutics Holdings, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
ACLX
Michelle GilsonCHIEF FINANCIAL OFFICERApr 16, 2026
Option Exercise
$8.662,110$18.3K67,048
ACLX
Michelle GilsonCHIEF FINANCIAL OFFICERApr 15, 2026
Option Exercise
$8.6636,000$311.8K64,938
ACLX
Michelle GilsonCHIEF FINANCIAL OFFICERFeb 25, 2026
Sale
$113.8211,219$1.3M33,938
ACLX
Michelle GilsonCHIEF FINANCIAL OFFICERJan 6, 2026
Option Exercise
$0.0020,530—64,832
ACLX
Gilson Michelle—Feb 25, 2026
Proposed Sale
$113.8211,219$1.3M—
ACLX
Gilson Michelle—Feb 19, 2026
Proposed Sale
$68.298,384$572.6K—
ACLX
Michelle GilsonCHIEF FINANCIAL OFFICERFeb 19, 2026
Sale
$68.298,384$572.6K45,157
ACLX
Michelle GilsonCHIEF FINANCIAL OFFICERJan 3, 2026
Option Exercise
$0.0015,340—44,302
ACLX
Michelle GilsonCHIEF FINANCIAL OFFICERFeb 17, 2026
Sale
$69.5111,291$784.8K53,541
ACLX
Michelle GilsonCHIEF FINANCIAL OFFICERJan 2, 2026
Option Exercise
$0.0020,496—28,962
ACLX
Gilson Michelle—Feb 17, 2026
Proposed Sale
$69.5111,291$784.8K—
ACLX
MICHELLE GILSON—Oct 15, 2025
Proposed Sale
$87.335,364$468.4K—
ACLX
MICHELLE GILSON—Oct 3, 2025
Proposed Sale
$82.245,946$489.0K—
ACLX
Gilson Michelle—May 27, 2025
Proposed Sale
$64.1412,235$784.8K—
ACLX
Gilson Michelle—Jan 7, 2025
Proposed Sale
$75.539,100$687.3K—
ACLX
MICHELLE GILSON—Jan 7, 2025
Proposed Sale
$75.019,252$694.0K—
ACLX
Gilson Michelle—Jan 3, 2025
Proposed Sale
$79.5513,000$1.0M—
ACLX
MICHELLE GILSON—Sep 17, 2024
Proposed Sale
$77.0115,000$1.2M—